NIH Grant Boosts Delpor’s Plans for Tizanidine Implant

NIH Grant Boosts Delpor’s Plans for Tizanidine Implant

312295

NIH Grant Boosts Delpor’s Plans for Tizanidine Implant

The development of Delpor‘s DLP-208 implant for the treatment of moderate-to-severe spasticity, a symptom that commonly affects people with multiple sclerosis (MS), has been boosted by a National Institutes of Health (NIH) grant. The $2.5 million grant will help the company advance DLP-208 into clinical testing, which is expected to happen by 2023. Recommended Reading November 8, 2021 News by Steve Bryson PhD Robotic Devices Help Improve Walking for Those with Severe Deficits If approved by…

You must be logged in to read/download the full post.